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Abstract Impaired glucose tolerance (IGT) which pre-
cedes overt type 2 diabetes (T2DM) for decades is asso-
ciated with multiple metabolic alterations in insulin
sensitive tissues. In an UPLC-qTOF-mass spectrometry-
driven non-targeted metabonomics approach we investi-
gated plasma as well as spot urine of 51 non-diabetic,
overnight fasted individuals aiming to separate subjects
with IGT from controls thereby identify pathways affected
by the pre-diabetic metabolic state. We could clearly
demonstrate that normal glucose tolerant (NGT) and IGT
subjects clustered in two distinct groups independent of the
investigated metabonome. These ﬁndings reﬂect consider-
able differences in individual metabolite ﬁngerprints, both
in plasma and urine. Pre-diabetes associated alterations in
fatty acid-, tryptophan-, uric acid-, bile acid-, and lyso-
phosphatidylcholine-metabolism, as well as the TCA cycle
were identiﬁed. Of note, individuals with IGT also showed
decreased levels of gut ﬂora-associated metabolites namely
hippuric acid, methylxanthine, methyluric acid, and 3-hy-
droxyhippuric acid. The ﬁndings of our non-targeted
UPLC-qTOF-MS metabonomics analysis in plasma and
spot urine of individuals with IGT vs NGT offers novel
insights into the metabolic alterations occurring in the long,
asymptomatic period preceding the manifestation of T2DM
thereby giving prospects for new intervention targets.
Keywords Metabolomics  UPLC-qTOF-MS 
Diabetes  Pre-diabetes  Impaired glucose tolerance
1 Introduction
Type 2 diabetes (T2DM), called the burden of the 21st
century, is growing with an epidemic rate (Alberti et al.
2007). The risk to develop this metabolic disease is
reﬂected by impaired glucose tolerance (IGT) (Unwin et al.
2002), which is diagnosed based on the results of an oral
glucose tolerance test (oGTT) according to the threshold
criteria deﬁned by the World Health Organization/the
International Diabetes Federation, or the American Dia-
betes Association (Nathan et al. 2007;W H O2006). Global
estimates of IGT are not available, but the number of
individuals with IGT is likely to be even greater than the
number with overt diabetes (Yach and Alberti 2003).
Independent of an elevated risk to develop T2DM affected
individuals experience an increased risk of cardiovascular
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DOI 10.1007/s11306-010-0203-1events and mortality (Festa et al. 2004; Novoa et al. 2005;
Petersen and McGuire 2005; Sorkin et al. 2005; Waugh
et al. 2007). To gain novel insights in the metabolic traits
reﬂecting a high risk to develop T2DM is an important
prerequisite for the understanding of the pathophysiology
of the long asymptomatic period of this heterogeneous
metabolic disease and for the development of new inter-
vention strategies to retard or even prevent the manifesta-
tion of overt T2DM.
It is well known that the metabolites in plasma, urine
and cerebrospinal ﬂuid reﬂect both normal variation and
the pathophysiological impact of diseases. These differ-
ences in metabolite patterns can give insight into
underlying molecular mechanisms. The generation of a
metabolic ﬁngerprint in body ﬂuids may be a powerful tool
to compare metabolic physiological and/or pathophysio-
logical changes at a given time point. Metabonomics,
recently introduced as the non-targeted analysis of metab-
olites (Holmes et al. 2008b; Lindon et al. 2003; Nicholson
and Lindon 2008; van der Greef et al. 2004), has been
proven in several recent human studies to fulﬁll these
prerequisite aiming to elucidate biomarkers of dietary and
cultural inﬂuences (Lenz et al. 2004), Parkinson’s disease
(Bogdanov et al. 2008), coronary heart disease (Brindle
et al. 2002), bowel disease (Marchesi et al. 2007), myo-
cardial infarction (Lewis et al. 2008), kidney cancer (Kind
et al. 2007), and prostate cancer (Sreekumar et al. 2009).
Thus, metabonomics investigations of body ﬂuids serve in
two distinct but closely related modes: as a metabolic ﬁn-
gerprinting tool separating groups based on altered meta-
bolic patterns and as a means to identify metabolites as
potential biomarkers discriminating between normal and
pathological states.
In the ﬁeld of diabetes research recently a number of
animal and a few human metabonomics studies had be
published investigating the metabolic effects of an oral
glucose challenge (Shaham et al. 2008; Wopereis et al.
2009; Zhao et al. 2009), insulin resistance (Chen et al.
2008; Plumb et al. 2006; Shaham et al. 2008; Shearer et al.
2008; Toye et al. 2007; Williams et al. 2006a, b), type 1
(Makinen et al. 2008; Zhang et al. 2008) or T2DM (Gipson
et al. 2008; Huo et al. 2009; Salek et al. 2007; van Doorn
et al. 2007; Zhang et al. 2009). However, currently only
two studies investigated pre-diabetic metabolic pattern in
humans (Shaham et al. 2008; Zhang et al. 2009). Shaham
et al. investigated in detail the time-dependent response to
a glucose challenge on distinct axes of insulin sensitivity
by targeted metabolic proﬁling of 191 plasma metabolites
(Shaham et al. 2008). In the study performed by Zhang
et al.
1H-NMR was applied for non-targeted metabonomic
analysis of serum samples from controls, pre-diabetic
subjects with impaired glucose regulation and individuals
with T2DM. A distinct clustering of controls and diabetic
subjects was demonstrated, however the analysis of pre-
diabetic individuals and controls resulted in no clear sep-
aration (Zhang et al. 2009).
Applying non-targeted metabonomics by UPLC-qTOF-
MS we aimed to investigate metabolic ﬁngerprints of pre-
diabetic subjects vs normal glucose tolerant controls in
plasma as well as spot urine. Based on the individual
metabolic ﬁngerprint, subjects with IGT were clearly sep-
arated from controls either in plasma or spot urine. We
identiﬁed metabolites reﬂecting speciﬁc alterations of
metabolic pathways. The detected pathway alterations offer
new insights in the complex dysregulation of the metabo-
lism in the pathogenesis of T2DM during the long
asymptomatic period of IGT giving prospects for novel
interventions targets like the gut ﬂora or fatty acid
metabolism.
2 Materials and methods
2.1 Human samples and oral glucose tolerance test
In total 51 subjects were included in the study group (age:
46.9 SE ± 11.9 years). All individuals underwent a 75 g
oGTT according to the recommendations of the WHO/IDF
to deﬁne normal (NGT) or IGT (WHO 2006). 39 were
diagnosed to have NGT and 12 to have IGT. For the
metabolomics investigations blood and spot urine samples
were collected after an overnight fasting under standard-
ized conditions and immediately stored in aliquots at
-80C. Analysis of routine laboratory parameters was
performed as described recently (Schafer et al. 2007). The
protocol of the study was approved by the Ethics Com-
mittee of the University Tuebingen conformed to the
Declaration of Helsinki, and all subjects gave written
informed consent. The investigation was conducted in
accordance with the ethical principles of Good Clinical
Practice.
2.2 Reversed-phase ultra performance liquid
chromatography coupled to electrospray ionization
quadrupole time of ﬂight mass spectrometry
(UPLC-qTOF-MS)
Plasma or urine sample aliquots were deproteinized with
two volume parts of acetonitrile, centrifuged
(13000 9 rpm for 20 min), run to dryness in a vacuum
centrifuge and stored at -20C. For analysis, the plasma
samples were reconstituted in 200 ll acetonitrile and water
(4:1), and urine samples were reconstituted in 200 ll
acetonitrile and water (1:4). The chromatographic separa-
tion was performed on a 100 9 2.1 mm ACQUITY
1.7 lm/C18 column at 35C using an ACQUITY-UPLC
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123system (Waters Corp, Milford, USA). We applied our
recently reported UPLC-qTOF-MS approach, established
and validated for the metabonomics analysis of serum and
urine (Yin et al. 2008; Zhao et al. 2008). For plasma
analysis the gradient program was 95% A (A = 0.1%
formic acid in water) for 0.5 min, changed to 100% B
(B = acetonitrile) linearly within 24 min and held for
4 min, ﬁnally back to 95% A (ﬂow rate 0.35 ml/min).
Urine samples were analyzed applying a gradient program
starting at 98% A (A = 0.1% formic acid in water) for
0.5 min, changed to 70% B (B = acetonitrile) linearly
within 25 min, then changed to 100% B and held for
3.5 min, ﬁnally back to 98% A (ﬂow rate 0.35 ml/min).
The UPLC system was coupled to a qTOF-MS (Micro-
mass, Manchester, UK) equipped with an electrospray
source operating in either positive or negative ion mode
The metabolites were detected and identiﬁed following our
recently published strategy for the identiﬁcation of
metabolite biomarkers (Chen et al. 2008).
2.3 Data pretreatment
For an efﬁcient evaluation of the metabolic variability
between NGT and IGT subjects, mass spectra were digi-
tally analyzed using the Micromass MarkerLynx Applica-
tions Manager version 4.0 (Waters Ltd, Manchester, UK).
The data were combined into a single matrix by aligning
peaks with the same mass and retention time together from
each data ﬁle in the data set. The intensity for each peak
was normalized to the sum of the peak intensities for each
data set. Metabolites which did not exist in 80% of NGT or
IGT subjects were ﬁltered. After that, the data were
exported into Soft Independent Modelling of Class Anal-
ogy (SIMCA)-P (version 11.0, Umetrics AB, Umea, Swe-
den) for analysis and visualization by multivariate
statistical methods.
2.4 Multivariate statistical analysis
The pre-processed UPLC-qTOF-MS data were exported
into Soft Independent Modelling of Class Analogy (SIM-
CA)-P (version 11.0, Umetrics AB, Umea, Sweden) for
analysis and visualization by multivariate statistical meth-
ods. After Pareto scaling and OSC-ﬁltering according to
Wold et al. (Wold et al. 1998), partial least squares-dis-
criminant analysis (PLS-DA) was applied. The predictive
ability of the model was assessed by internal validation
using 7-fold cross-validation and response permutation
testing. For the detection of metabolite ion masses with
major inﬂuence on the group membership the S-plot was
used according to (Wiklund et al. 2008). The metabolite
heat map was generated using MultiExperiment View V4.1
(www.tm4.org). The Wilcoxon Rank Sum test for the
comparison of clinical chemical and oGTT data of the IGT
vs NGT individuals were computed using the statistical
software packet JMP (SAS Institute, Inc., Cary, NC).
Statistical signiﬁcance was set at P\0.05.
3 Results
3.1 Analysis of the individual metabolite ﬁngerprint
infastingplasmaandspoturinebyUPLC-qTOF-MS
in normal and impaired glucose tolerant subjects
Each subject (n = 51) was characterized by clinic check-up
and the analysis of clinical chemical routine parameters in
blood and urine to exclude subjects with disease of the
cardiovascular system, the kidney or the liver, as well as
severe inﬂammation (Table 1). Furthermore, an oGTT was
performed to detect potential diabetic individuals and
moreover to identify individuals with IGT. The comparison
between 39 control and 12 IGT subjects showed, besides
parameters of glucose metabolism, also a signiﬁcant dif-
ference in the inﬂammatory marker C-reactive protein
(CRP). This is not an unexpected ﬁnding since low-grade
inﬂammation, i.e. within the reference interval for CRP, is
well-knownin the pathogenesis of pre-diabetes and diabetes
(Cefalu 2009). No difference was detected in the parameters
reﬂecting kidney function, namely creatinine and uric acid
in plasma, total protein and albumin in urine (see Table 1),
which is an important prerequisite for the non-targeted
metabonomics analysis of urine and plasma since renal
dysfunction may greatly inﬂuence the metabolite compo-
sition in these body ﬂuids. The body mass index was also
not signiﬁcantly different between the NGT and the IGT
group (30.76 ± 1.15 vs 34.60 ± 2.0; P = 0.1121).
For analysis of the individual metabolite ﬁngerprint, we
applied our recently reported UPLC-qTOF-MS approach
(Yin et al. 2008; Zhao et al. 2008). The relative standard
deviation (RSD) of retention times of the main peaks was
less than 1%, and the RSD of peak area was less than 10%.
These data represented a good repeatability of retention
times and a satisfactory precision of quantitation. Therefore
the method was reliable for the subsequent analysis of
metabolite ﬁngerprints in human body ﬂuids.
For each sample, reversed-phase UPLC-qTOF-MS
analysis was applied in the positive and negative ESI mode
to increase the number of detected metabolite ions. Fig-
ure 1a shows a typical base peak intensity chromatogram
(BPC) of plasma recorded in the positive ionization mode,
and Fig. 1b shows the BPC of plasma recorded in the
negative ionization mode. The BPCs of urine are given in
Fig. 1c and d, respectively. After peak alignment, the
datasets of plasma contained 2122 metabolite ions (1161 in
364 X. Zhao et al.
123positive and 961 in negative ionization mode) and of spot
urine 2574 metabolite ions (1060 in positive and 1514 in
negative ionization mode). The pre-processed UPLC-
qTOF-MS data were further investigated using multivariate
statistical analyses.
3.2 Comparison of the individual metabolite
ﬁngerprints by multivariate data analysis
To determine whether the metabolite ﬁngerprints in fasting
plasma and/or spot urine differs between NGT and IGT in
our metabonomics approach, we constructed two compo-
nent PLS-DA models. NGT and IGT individuals are clearly
divided in two distinct clusters in the PLSA-DA scores plot
independent if plasma (Fig. 2a) or urine (Fig. 2b) was
used. To ensure that the calculated models are reliable and
the observed clustering is not due to chance, we performed
an internal validation using 7-fold cross-validation (Eriks-
son et al. 2001). The calculated goodness of ﬁt (R
2Y) was
0.99 for plasma, and 0.95 for urine and the goodness of
prediction (Q
2Y) of 0.96 for plasma and 0.76 for urine,
respectively which underlines the robustness of the model.
In addition a response permutation test (Eriksson et al.
2001) was used to conﬁrm the signiﬁcance of the predictive
ability. The separation is more pronounced in plasma in
comparison to the non-invasively collected urine samples,
which may be a hint to more evident alterations in the
metabolite pattern of plasma but may be also a conse-
quence of the higher sample variability in urine (Lenz et al.
2003, 2004).
Since the population sizes of 39 NGT and 12 IGT
subjects are different, which may affect the multivariate
data analysis and consequently the clustering of the groups,
we repeated the data evaluation by randomly separating the
control (NGT) group into three subgroups, each consisting
out of 13 individuals. In the score plots of these two-
component PLS-DA models (Fig. S1A, S1B, S1C for
plasma, and Fig. S2A, S2B, S2C for urine, shown in the
supporting information of the supplementary material) it
became obvious that each NGT subgroup can be clearly
separated from the IGT group. For plasma, the calculated
goodness of ﬁt (R
2Y) was 0.995, 0.986 and 0.995, and the
goodness of prediction (Q
2Y) was 0.948, 0.915 and 0.939,
respectively. For urine, the calculated goodness of ﬁt (R
2Y)
was 0.998, 0.996 and 0.993, and the goodness of prediction
(Q
2Y) was 0.729, 0.715 and 0.590, respectively. These
Table 1 Routine laboratory parameters of the study group
Normal glucose tolerance
(n = 39) mean ± SEM
Impaired glucose tolerance
(n = 12) mean ± SEM
Reference
values
a
P-values
Blood parameter
2 h plasma glucose [mmol/l] 6.19 ± 0.17 9.35 ± 0.38 \7.8
b \0.0001
Glucose (fasting) [mmol/l] 5.10 ± 0.07 5.68 ± 0.16 \5.6 0.0004
Insulin (fasting) [pmol/l] 62.08 ± 7.8 94.89 ± 15.70 \185 0.052
HbA1c [%] 5.85 ± 0.05 6.13 ± 0.15 \6.1 0.026
Triglycerides [mg/dl] 107.9 ± 9.6 123.3 ± 10.5 \150 0.405
Cholesterol [mg/dl] 190.3 ± 5.8 186.6 ± 8.5 \190 0.746
LDL-cholesterol [mg/dl] 121.9 ± 5.1 120.8 ± 8.5 \160 0.916
HDL-cholesterol [mg/dl] 52.1 ± 2.0 46.2 ± 2.6 [35 0.136
C-reactive protein [mg/dl] 0.20 ± 0.03 0.41 ± 0.09 \0.5 0.007
Leukocytes [1/ll] 6348 ± 249 5955 ± 273 4000–9500 0.412
Total protein [mg/dl] 7.0 ± 0.06 6.9 ± 0.11 6.5–8.5 0.800
Creatinine [mg/dl] 0.99 ± 0.02 0.99 ± 0.03 \1.1 0.913
Uric acid [mg/dl] 5.5 ± 0.26 6.2 ± 0.31 3.4–7.0 0.178
Homocysteine [lmol/l] 10.0 ± 0.56 9.3 ± 0.55 \15 0.500
Urine parameter
Total protein [mg/g creatinine] 143.7 ± 16.1 124.8 ± 19.9 \150 0.543
Albumin [mg/g creatinine] 10.0 ± 1.2 17.8 ± 6.6 \20 0.068
Creatinine [g/l] 0.85 ± 0.09 0.98 ± 0.17 0.8–2.0 0.446
pH-value 6.0 ± 0.15 6.1 ± 0.19 4.8–7.4 0.661
Based on the 2 h blood glucose value individuals were divided in groups of normal and impaired glucose tolerance according to the recom-
mendations of the WHO/IDF (WHO 2006). Data shown as (average) mean ± standard deviation (Standard Error of the Mean = SEM)
a From the University Hospital of Tuebingen, Germany
b According to the deﬁnition of the WHO
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123values are comparable to the data achieved in the two-
component PLS-DA model constructed from 39 NGT and
12 IGT individuals (Fig. 2). Thus, the results show that
unbalance of the two groups has no effect on the classiﬁ-
cation. Therefore we continued using 39 NGT subjects as
control group for further data analysis.
3.3 Identiﬁcation of plasma and urinary metabolites
related to pre-diabetic alterations of metabolic
pathways
For mining the complex data to propose which metabolites
are potentially biochemical interesting compounds we used
the S-plot of SIMCA-P according to literature (Wiklund
et al. 2008). It is a scatter plot which combines the
covariance and correlation loading proﬁles resulting from
the predictive component of the OSC-ﬁltered PLS-DA
scores plot (Wiklund et al. 2008). The S-plots given in
Fig. 3 show the m/z values of the most altered metabolite
ions in plasma and spot urine of IGT subjects. The
metabolite ions with the greatest inﬂuence on the clustering
in the PLS-DA score plots (Fig. 2) are located furthest
away from the center of the S-plot shown in Fig. 3a for
plasma and Fig. 3b for urine.
The metabolites were identiﬁed following our recently
published strategy (Chen et al. 2008). Accurate mass and
mass spectrometric fragmentation pattern was utilized to
search databases including KEGG, PubChem compound,
METLIN, and HMDB database. Standard samples were
used for the conﬁrmation of the identity of ambiguous
compounds. A summary of identiﬁed metabolites is given
in Table 2 (for plasma) and Table 3 (for urine).
The most discriminative plasma metabolites separating
IGT and NGT subjects were the saturated free fatty acid
(FFA) palmitate, the unsaturated FFA oleate, and the sat-
urated FFA stearate. Additionally, the FFAs C18:2, C16:1,
C20:4 and C22:4 were also detected to be increased in
plasma of IGT subjects (Table 2). Furthermore, the bile
acid glycochenodeoxycholic acid, as well as lyso-phos-
phatidylcholines (LPCs) are discriminative plasma metab-
olite biomarkers classifying normal and impaired glucose
tolerant individuals. The pre-diabetic metabolic state
resulted in increased relative plasma levels of free fatty
acids (C16:0, C18:0, C18:1, C18:2, etc.) and bile acid
(glycochenodeoxycholic acid), as well as decreased plasma
levels of LPC (C16:0 and C18:2 etc.; Table 2). Since
reversed-phase chromatography was used highly polar
potential biomarkers, like glucose, could not be detected in
our approach.
In the S-plot of urine, we detected decreased levels of
hippuric acid, uric acid, 3-hydroxyhippuric acid, phenylace-
tyl-glutamine (PAGN), methyluric acid and methylxanthine,
Fig. 1 Representative UPLC-
ESI-qTOF-MS base peak
intensity chromatograms (BPC)
(m/z 100–700; 0–25 min) from
a human plasma sample
analyzed in positive (a) and in
negative ionization mode (b),
and from a spot urine in positive
(c) and in negative ionization
mode (d). Methodological
details are given in the
‘‘Method’’ section
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123whereas the urinary excretion of C8:2-OH carnitine, C10:2-
OH carnitine, xanthine and tryptophan was increased
(Table 3).
Since FFAs and LPCs were the dominating biomarkers
detected a metabolite heat map was generated to study the
alterations of the signal intensity of FFAs and LPCs in
plasma of the 51 subjects (Fig. 4a). Plasma levels were
represented by colors in the heat map, and each FFA and
LPC was represented by a single row of colored boxes,
whereas columns represented different subjects. The yel-
low labels show increase, and the blue labels means
decrease intensities relative to the median metabolite lev-
els. The heat map revealed considerable differences
between NGT and IGT subjects. In IGT subjects with a 2-h
glucose level above 7.8 mmol/l (marked by a red line)
increased FFAs and decreased LPC levels are visible. In
contrast to that in the heat map region of subjects with 2-h
glucose levels less than 6.4 mmol/l FFAs showed
decreasing and LPCs increasing levels. In subjects with a
2-h glucose below 5 mmol/l the pattern is inverse to the
IGT group. In region of 2-h plasma glucose between 6.4
and 7.8 mmol/l a transition pattern was detected. Based on
these ﬁndings student’s t test was performed to evaluate
statistically signiﬁcances in FFA and LPC levels (Fig. 4b
and c). In the NGT group a tendency for lower plasma
levels of the saturated fatty acids palmitate (P = 0.08) and
stearate (P = 0.07) were detected, but not for the mono-
and poly-unsaturated FFAs oleate and arachidonic acid.
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Fig. 2 Two dimensional scores
plot of a partial least squares-
discriminant analysis (PLS-DA)
with orthogonal signal
correction (OSC) data ﬁlter of
the ﬁrst and second PLS
component of (a) plasma and
(b) spot urine. Normal glucose
tolerant (NGT) individuals are
labelled by open squares and
impaired glucose tolerant (IGT)
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123LPCs (C16:0; C18:0, C18:1; C18:2) all tended to be
increased in the NGT group. Based on the signatures in the
heat map we performed also a comparison of the IGT and
subjects with 2-h glucose below 6.4 mmol/l which resulted
in signiﬁcant differences (P\0.05) in all LPCs and pal-
mitate as well as stearate.
4 Discussion
Impaired glucose tolerance is a polygenetic and environ-
mentally determined metabolic disease. To study these
pre-diabetic metabolic traits we applied an UPLC-qTOF-
MS-based non-targeted metabonomics approach for the
investigation of plasma and spot urine of subjects with IGT
vs controls. Independent from the body ﬂuid used the
individual metabolite ﬁngerprints led to a clear discrimi-
nation of pre-diabetic individuals from the control group
with normal glucose tolerance. Identiﬁcation of discrimi-
nating metabolites revealed alterations of various meta-
bolic pathways and a metabolite heat map of plasma free
fatty acids and lysophosphytidylcholines revealed a close
relationship of changes of the plasma heat map pattern of
FFA and LPCs to the 2-h oGTT glucose levels.
The most discriminative metabolites in plasma showing
an increased level in pre-diabetic individuals were the free
Fig. 3 S-plot of (a) plasma and
(b) spot urine. The variables are
labeled with m/z values.
Potential metabolic biomarkers
including the corresponding m/z
values are presented in Tables 2
and 3
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123fatty acids, including e.g. C16:0, C18:0, C18:1 and C20:4
(Table 2). Since insulin effects are impaired in IGT sub-
jects, reduced insulin-mediated inhibition of lipolysis and
attenuated stimulation of lipid storage in adipose tissue as
well as increased hepatic output leads to increased circu-
lating free fatty acids and triglycerides (Montecucco et al.
2008; Stumvoll et al. 2000). These increased blood levels
may result in enhanced b-oxidation in liver and in skeletal
muscle. This assumption is supported by our ﬁnding of
increased urinary excretion of acylcarnitines (Table 3),
which reﬂect the substrate ﬂux through b-oxidation and are
therefore ‘‘readouts’’ of it (Koves et al. 2008) and com-
monly used to screen for inborn metabolic disorders (Van
Hove et al. 1993). Hence, the ﬁndings of our LC–MS-
driven non-targeted approach are well in line with a current
model discussed by the group of Muoio where lipid over-
supply induced insulin resistance in muscle is explained by
‘‘overload’’ of mitochondrial lipid oxidation, accumulation
of acylcarnitines, and depletion of TCA intermediates
which may lead to mitochondrial stress activating currently
unknown signaling pathways that interfere with insulin
action (Bain et al. 2009; Koves et al. 2005; Koves et al.
2008). A scheme, given in Fig. 5, illustrates the concept of
increased lipolysis in adipose tissue and hepatic and mus-
cular lipid oversupply in the pre-diabetic state. As a con-
sequence the triglyceride storage in the liver and the
Table 2 List of plasma
metabolites most inﬂuential in
discriminating between NGT
and IGT individuals in the
S-plot shown in Fig. 3a
The metabolites were divided in
groups of increasing and
decreasing signal intensities and
sorted by retention time
a ESI? means positive
electrospray ionization mode
and ESI- means negative
electrospray ionization mode,
respectively
b Relative metabolite level in
plasma of IGT subjects in
comparison to NGT individuals
Retention time
(min)
m/z Ionization
mode
a
Mass
accuracy (ppm)
Metabolite Change
b
4.56 186.9711 ESI- ui :
12.05 448.3051 ESI- 2.6 Glycochenodeoxycholic acid :
19.66 253.2159 ESI- 3.7 FFA C16:1 [M - 1]
- :
19.88 303.2315 ESI- 3.1 FFA C20:4 [M - 1]
- :
20.18 329.2466 ESI- 4.6 FFA C22:5 [M - 1]
- :
20.19 279.2314 ESI- 3.5 FFA C18:2 [M - 1]
- :
20.81 305.2472 ESI- 2.9 FFA C20:3 [M - 1]
- :
21.37 331.2624 ESI- 3.9 FFA C22:4 [M - 1]
- :
21.50 255.2313 ESI- 4.2 FFA C16:0 [M - 1]
- :
21.51 256.2395 ESI- 3.2 Isotope of FFA C16:0 [M - 1]
- :
21.73 282.2553 ESI- 2.4 Isotope of FFA C18:1 [M - 1]
- :
21.73 281.2475 ESI- 2.2 FFA C18:1 [M - 1]
- :
22.04 307.2627 ESI- 3.1 FFA C20:2 [M - 1]
- :
23.37 283.2627 ESI- 3.4 FFA C18:0 [M - 1]
- :
9.05 367.1643 ESI- ui ;
14.49 504.3154 ESI- 2.7 LPC C18:2 [M - CH3]
- ;
14.49 564.3284 ESI- 3.1 LPC C18:2 [M ? HCOO]
- ;
14.54 520.3392 ESI? 2.1 LPC C18:2 [M ? 1]
? ;
14.54 184.0733 ESI? 3.5 Fragment of LPC C18:2 ;
14.77 476.3046 ESI- ui ;
14.84 504.3148 ESI- 3.9 LPC C18:2 [M - CH3]
- ;
15.30 480.3069 ESI- 4.5 LPC C16:0 [M - CH3]
- ;
15.31 540.3284 ESI- 3.2 LPC C16:0 [M ? HCOO]
- ;
15.39 184.0733 ESI? 3.1 Fragment of LPC C16:0 ;
15.75 480.3073 ESI- 3.7 LPC C16:0 [M - CH3]
- ;
15.75 540.3286 ESI- 2.8 LPC C16:0 [M ? HCOO]
- ;
15.85 506.3237 ESI- 1.9 LPC C16:1 [M - CH3]
- ;
15.85 566.3444 ESI- 2.4 LPC C18:1 [M ? HCOO]
- ;
15.93 496.3393 ESI? 2.1 LPC C16:0 [M ? H]
? ;
15.93 184.0733 ESI? 3.2 Fragment of LPC C16:0 ;
16.21 506.3233 ESI- 2.8 LPC C18:1 [M - CH3]
- ;
16.86 494.3236 ESI- 1.9 ui ;
17.57 568.3602 ESI- 2.1 LPC C18:0 [M ? HCOO]
- ;
17.64 184.0735 ESI? 2.4 Fragment of LPC C18:0 ;
18.03 568.3601 ESI- 2.2 LPC C18:0 [M ? HCOO]
- ;
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123hepatic output of very-low-density lipoproteins is
increased. In skeletal muscle the augmented mitochondrial
lipid oxidation may lead to accumulation of b-oxidation
intermediates and depletion of TCA intermediates which
then may be reﬂected by the detected increased urinary
excretion of acyl-carnitines and decreased excretion of
phenylacetyl-glutamine in our study (Fig. 5). Though we
ﬁnd most of detected free fatty acids increased in IGT
individuals in the heat map (Fig. 4a), saturated free fatty
acids (SFA; C16:0 and C18:0) increased more pronounced
than mono-unsaturated free fatty acids (C16:1, C18:1) and
poly-unsaturated fatty acids (C18:2, C20:4, C22:4 etc.;
Fig. 4a). Compared with the NGT group (2 h oGTT glu-
cose less than 7.8 mmol/l), mean peak area of SFA C16:0
and C18:0 in the IGT group increased 66% and 26%,
respectively (Fig. 4b), but this tendency was not signiﬁ-
cant. A signiﬁcant difference was detected when IGT
subjects and individuals with 2-h oGTT glucose levels
\6.4 mmol/l were compared. SFA have been shown to
exert lipotoxic effects like the induction of apoptosis,
inﬂammation, and endoplasmatic reticulum stress that are
associated with metabolic diseases (Borradaile et al. 2006;
Eizirik et al. 2008; Peter et al. 2008; Staiger et al. 2004;
Stefan et al. 2008; Weigert et al. 2004).
An increased level of the bile acid glycochenodeoxy-
cholic acid (GCDCA, m/z 448.29 in ESI
-) was also
detected in the fasting plasma of the pre-diabetic individ-
uals in our study. Bile acids have recently evolved from
detergents that emulsify nutrient lipids and remove
cholesterol from the body to systemic signaling molecules
(Thomas et al. 2008) and novel functions of bile acids as
metabolic integrators of whole body energy homeostasis
that inﬂuence glucose and lipid metabolism have been
discovered (Thomas et al. 2008). Whether GCDCA
reﬂects a general alteration of the bile acid metabolism
under the pathophysiological conditions or if it is solely
discriminating between NGT and IGT under fasting con-
ditions needs to be proven. However, using a multi-ana-
lytical platform approach Wilson’ group detected
taurocholic acid in obese Zucker (fa/fa) rats—an important
disease model to study obesity and onset of insulin
resistance, as one of the discriminating biomarkers, being
increased in plasma (Plumb et al. 2006; Williams et al.
2006a) and decreased in urine (Williams et al. 2006b).
Furthermore, one of the most striking changes during a
120 min oGTT in healthy humans was the dramatic
increases of bile acids, very recently detected in a targeted
metabolic proﬁling approach studying the proﬁle of 191
plasma metabolites (Shaham et al. 2008) and by our group
in a non-targeted metabolomics study (Zhao et al. 2009).
Of note, applying a model relating fasting insulin to
120 min metabolite change in individuals with IGT Sha-
mam et al. could show that pre-diabetic individuals had a
greater change in the excursion of GCDCA compared with
controls (Shaham et al. 2008). The excursion of lactate,
valine, methionine, b-hydroxybutyrate and leucine/isoleu-
cin were also different in the pre-diabetics (Shaham et al.
2008).
Table 3 List of metabolites in
the S-plot most inﬂuential in
discriminating between NGT
and IGT individuals in urine
shown in Fig. 3b
The metabolites were divided in
groups of increasing and
decreasing signal intensities and
sorted by retention time
a ESI? means positive
electrospray ionization mode
and ESI- means negative
electrospray ionization mode,
respectively
b Relative metabolite level in
urine of IGT subjects in
comparison to NGT individuals
Retention
time (min)
m/z Ionization
mode
a
Mass accuracy
(ppm)
Metabolite Change
(b)
1.91 153.0399 ESI? 8.9 Xanthine [M ? 1]
? :
6.65 195.0311 ESI- ui :
6.82 188.0702 ESI? 4.2 Fragment of tryptophan :
19.24 300.1803 ESI? 2.5 C8:2-OH carnitine [M ? 1]
? :
23.09 328.2117 ESI? 2.1 C10:2-OH carnitine [M ? 1]
? :
1.00 169.0351 ESI? 6.3 Uric acid [M ? 1]
? ;
1.03 167.0198 ESI- 4.3 Uric acid [M - 1]
- ;
2.37 167.0482 ESI? 5.1 7-methylxanthine [M ? 1]
? ;
2.45 183.0511 ESI? 3.9 Methyluric acid M ? 1]
? ;
2.50 181.0431 ESI- 4.7 Methyluric acid [M - 1]
- ;
2.77 167.0483 ESI? 4.9 3-methylxanthine [M ? 1]
? ;
3.10 167.0481 ESI? 5.8 1-methylxanthine [M ? 1]
? ;
4.97 181.0671 ESI? 4.9 ui ;
6.14 194.0446 ESI- 3.7 3-hydroxyhippuric acid [M - 1]
- ;
8.62 105.0334 ESI? 5.3 Fragment of hippuric acid ;
8.67 134.0602 ESI- 6.1 Fragment of hippuric acid ;
8.67 178.0500 ESI- 2.4 Hippuric acid [M - 1]
- ;
9.77 287.0998 ESI? 3.6 Phenylacetyl-glutamine [M ? Na]
? ;
11.7 187.0031 ESI- ui ;
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123Another group of metabolites identiﬁed in our study to
reﬂect pathophysiological alterations in IGT were the lys-
ophosphatidylcholines (LPCs), showing decreased plasma
levels in the heat map (Fig. 4a) and in the comparison of
signal intensities of selected LPCs (Fig. 4c). These ﬁndings
are similar to our previous investigation in individuals with
manifest T2DM (Wang et al. 2005).
Of note in urine, we detected that decreased urinary
levels of gut microbiota-associated metabolite biomarkers
i.e. hippuric acid, methylxanthine, methyluric acid and
3-hydroxyhippuric acid are related to IGT. In humans the
role of gut ﬂora in health is well recognized (Nicholson
et al. 2005) and accumulating evidence indicates that the
gut microbiota is instrumental in energy metabolism and
immune function of the host (Jia et al. 2008). Recent
reports from the group of J.K. Nicholson demonstrated the
association of diet and gut microbial activities with the
human metabolic phenotype (Li et al. 2008) and the blood
pressure of individuals (Holmes et al. 2008a). Furthermore
the group of Gordon demonstrated in animal and human
studies by sequencing faecal bacterial 16S rRNA genes that
variation in gut microbial composition is an important
factor in the aetiology of obesity and insulin resistance
(Ley et al. 2006; Turnbaugh et al. 2006; Turnbaugh et al.
2009). Thus, our metabonomics results may be an addi-
tional hint supporting the relevant role of the gut micro-
biota in the pathogenesis of the pre-diabetic state.
Furthermore we detected in urine increased levels of
xanthine, and tryptophan, while the level of phenylacetyl-
glutamine (PAGN) was decreased. The decreased excretion
of PAGN in IGT subjects may reﬂect differences in glu-
coneogenesis and/or TCA cycle intermediates. PAGN is
formed in the liver of humans and primates from glutamine
which is in equilibrium with glutamate and a-ketoglutarate
and phenylacetate (Yang and Brunengraber 2000).
Metabonomics investigations of pre-diabetic animal mod-
els as well as human studies of manifest T2DM are well in
line with our ﬁndings of alterations in TCA cycle inter-
mediates (Salek et al. 2007; Shearer et al. 2008; Williams
et al. 2006b; Zhang et al. 2009). In human serum of
individuals with manifest T2DM a recent non-targeted
1H-NMR metabolomics study revealed decreased citrate
Fig. 4 (a) Heat map of plasma free fatty acids (FFA) and
lysophsphatidylcholines (LPCs) of 39 healthy subjects with normal
glucose tolerance (NGT) and 12 individuals with impaired glucose
tolerance (IGT). The row above the heat map shows the m/z values of
these metabolites corresponding to Table 2. Individual 2-h oGTT
plasma glucose level in increasing order are given in the column to
the right. Cells are colored based on the signal intensity measured in
plasma. Yellow represents high plasma levels and blue showed low
signal intensity (see color scale above the heat map). A red line is
drawn at a 2-h plasma glucose concentration of 7.8 mmol/l
representing the WHO deﬁnition for the separation of NGT and
IGT. Furthermore, arrows are drawn at the 2-h plasma glucose
[5 mmol/l and [6.4 mmol/l where the heat map pattern shows
distinct changes. (b) and (c) differences in FFA and LPCs levels
between controls and pre-diabetic subjects were examined using
Student’s t-test. (b) comparison of the plasma signal intensities of free
fatty acids FFA (mean peak area ± standard error; * P\0.05, IGT
vs. the subgroup of NGT with a 2-h plasma glucose level below
6.4 mmol/l) and (c) lysophosphatidylcholines LPC (mean peak
area ± standard error; * P\0.05, IGT vs. subgroup of NGT with a
2-h plasma glucose level below 6.4 mmol/l). blue ﬁlled square IGT
group (n = 12), red ﬁlled square NGT group (n = 39), yellow ﬁlled
square subgroup of NGT with a 2-h plasma glucose level below
6.4 mmol/l (n = 22). (Color ﬁgure online)
b
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123levels (Zhang et al. 2009). Salek et al. compared metabolite
proﬁles in urine from unmedicated humans with T2DM,
db/db mice and fa/fa rats (Salek et al. 2007). They found
decreased urinary a-ketoglutarate excretion in the diabetic
state. Another major ﬁnding of this study was that changes
in metabolites involved in nucleotide, methylamine
metabolism and TCA cycle intermediates were common
between the animal models and humans (Salek et al. 2007).
We conclude that not only in the diabetic stage, but also in
the latent pre-diabetic phase, i.e. long before the manifes-
tation of diabetes, a dysregulation of the TCA cycle occurs.
5 Concluding remarks
Impaired glucose tolerance is widely present throughout
the general population (Abdul-Ghani et al. 2006) and
studies suggest that this pre-diabetic state is associated with
insulin resistance in muscle, liver and fat as well as a
defective insulin secretion resulting in multiple metabolic
traits (Abdul-Ghani et al. 2006). Although IGT is not a
clinical entity, it is a risk factor for future diabetes and/or
adverse outcomes (e.g. cardiovascular disease) (WHO
2006). A metabonomics approach based on UPLC qTOF
MS has been used to analyze individual metabolite ﬁn-
gerprints in plasma as well as in spot urine from overnight
fasted individuals. The investigation of a single body ﬂuid
sample, either plasma or spot urine led to a clear separation
of the clusters of pre-diabetic subjects and controls. The
identiﬁcation of discriminating metabolites revealed path-
ways affected by the pre-diabetic metabolic state. Altera-
tions in fatty acid-, tryptophan-, uric acid-, bile acid-,
lysophosphatidylcholine-metabolism, and the TCA cycle
were identiﬁed. The alterations in the levels of saturated
free fatty acids are more pronounced than mono-unsatu-
rated and poly-unsaturated free fatty acids. Of note, also
decreased levels of the gut ﬂora-associated metabolites
hippuric acid, methylxanthine, methyluric acid, and 3-hy-
droxyhippuric acid were detected in pre-diabetic individ-
uals. The present study shows in fasting plasma and urine
metabolic pathway alterations reﬂecting metabolic traits in
individuals at high risk to develop T2DM.
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